Long Term Outcome of 112 Pediatric Patients With Ureteropelvic Junction Obstruction Treated by Endourologic Retrograde Balloon Dilatation

Javier Ordóñez 1, Rubén Ortiz 1, Alberto Parente 2*, Laura Burgos 1, Beatriz Fernández-Bautista 1, Laura Pérez-Egido 1 and José María Angulo 1

1 Pediatric Urology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2 Reina Sofia University Hospital, Córdoba, Spain

Purpose: To analyze the effectiveness, complications and long-term outcome of the patients with ureteropelvic junction obstruction (UPJO) treated by endoscopic retrograde balloon dilatation (ERBD) in the largest series reported.

Materials and Methods: Between years 2004 and 2018, 112 patients with primary unilateral UPJO were treated by ERBD. Endoscopic treatment consisted on a retrograde balloon dilatation of the ureteropelvic junction (UPJ), through cystoscopy and under fluoroscopic guidance, using high-pressure balloon catheters. In case of persistence in the balloon notch, a Cutting Balloon™ catheter was used. Double-J stent was placed after dilatation.

Results: Mean age at surgery was 13.1 ± 21.3 months, 92 cases being younger than 18 months. Mean operative time was 24.4 ± 10.3 min; hospital stay was 1 day in 82% of patients. No intraoperative complications occurred. UPJ was calibrated at time of stent removal with cystoscopy 39.1 ± 13.7 days after dilatation. ERBD was not possible in 11 cases. An additional procedure was needed in 24 cases: second ERBD (n = 11, seven during the stent withdrawal), a third dilatation (n = 3) due to persistent hydronephrosis, and percutaneous endopyelotomy (n = 3) or open pyeloplasty (n = 7) in cases of technical failure. Significant improvement in postoperative ultrasound measures were observed (p < 0.05, T-test). Long-term success rate was 76.8% after one dilatation, and 86.6% in those who required up to 2 dilatations. Mean follow-up was 66.7 ± 37.5 months.

Conclusions: ERBD is a feasible and safe option for the minimally invasive treatment of UPJ obstruction in infants. Long-term outcome is acceptable with a very low complication rate.

Keywords: endourology, ureteropelvic junction obstruction, high-pressure balloon dilatation, pediatric urology, minimally invasive approach

INTRODUCTION

The treatment of the ureteropelvic junction obstruction (UPJO) in children is changing in recent years, with a greater tendency to perform minimally invasive approaches. Open pyeloplasty has demonstrated a success rate of over 94% (1, 2). Recent publications report an increasing effectiveness of the robot-assisted (3), laparoscopic (4) and endourologic approaches (5, 6). The
principal advantages of these techniques (reduction of postoperative pain, length of hospital stay, better cosmesis, etc.), together with their effectiveness and safety, are making them considered as the first therapeutic option in many cases (7, 8).

Endourologic balloon dilatation for the treatment of UPJO, widely used in the adult population, was first described in 1982 (9–11). The experience and outcomes in children are more limited. Pediatric sized instruments and technical improvement in the last years made it a safe and feasible approach for small children. Thus, the endourologic approach has been successfully used in the treatment of other obstructive urologic conditions [such as the primary obstructive megaureter (12, 13)], and in secondary UPJO (14–16). But the role of the endourologic treatment for the primary UPJO has been largely questioned, with discrepancy in the success rates and outcomes published (5, 6, 17).

In the present study, we report our experience in the management of primary UPJO treated by endourologic retrograde balloon dilatation (ERBD), which is established as first line of treatment in our institution (5). Furthermore, the peripheral cutting balloon microsurgical dilatation device (18) (Cutting Balloon™, CB) has been used in those patients that presented an incomplete resolution of the narrowing during the high-pressure balloon (HPB) dilatation. The aim of the study is to analyze the effectiveness, complications, and long-term outcomes of ERBD of primary UPJO in the largest pediatric series reported.

**MATERIALS AND METHODS**

After the institutional review board approval, we retrospectively analyzed all pediatric patients with unilateral primary UPJO treated by ERBD between July 2004 and September 2018 in our institution. Exclusion criteria were bilateral UPJO requiring intervention, associated urological anomalies [vesicoureteral reflux, extrinsic UPJO (as the presence of a polar vessel), obstructive primary megaureter, ureterocele, etc.] and a postoperative follow-up period lower than 18 months.

Hydronephrosis grade was defined according to the guidelines of the Society of Fetal Urology Classification and Urinary Tract Dilatation Grading System (19, 20). Ultrasound scan (at second day of life in cases of prenatal diagnosis, 1 month of life and every 3 months, under conservative surveillance with low-dose antibiotic prophylaxis) was used to measure the anteroposterior pelvis diameter, calyces and renal parenchyma thickness. Preoperative ultrasound showed grade IV hydronephrosis in all patients. Mercaptoacetyltrylglycine (MAG-3) renal scans with furosemide washout revealed obstructive pattern in all cases, with a washout halftime T1/2 > 50 min (21). In all cases, a micturating cystourethrogram was previously performed to rule out the presence of vesicoureteral reflux (exclusion criteria).

During those years, all patients with primary UPJO were treated with ERBD.

Clinical data, ultrasonography images, scintigraphy scans, and outcome were preoperatively and post-operatively analyzed. Intraoperative and perioperative complications were assessed according Clavien-Dindo classification. Statistical analysis was performed using IMB® SPSS® Statistics Version 25. Analysis of continuous variables was performed using the t-student test.

**Technique Description**

Under general anesthesia, with appropriate antibiotic prophylaxis and patient in lithotomy position, a cystoscopy is performed using a 9.5 Fr cystoscope with a 5 Fr instrumentation channel. A 4 Fr catheter is placed in the affected ureter in order to perform a retrograde pyelography. A hydrophilic guidewire (0.014” Choice PT™, J-tip, Boston Scientific; or 0.018” Radiofocus® Terumo) is negotiated up to the renal pelvis. In case of difficulties, a 0.035” hydrophilic guidewire is used (it travels easier in the retrograde direction inside the ureteral lumen). Then, a 3 Fr high-pressure balloon catheter is inserted over the guidewire and located in the UPJ, under fluoroscopic guidance. The balloons used were semi-compliant dilatation catheters with nominal diameter of 5–7 mm according to the patient’s weight (5 mm in patients <6 kg, 6 mm in 6–10 kg, and 7 mm in >10 kg) and 2 cm length (RX Muso™, Terumo). When the balloon is located at the UPJ, it is filled with radiologic contrast to its nominal pressure (14–16 atm) under fluoroscopic control until the balloon notch or hourglass image disappears. After successful dilatation procedure, a double-J ureteral stent is placed (3 Fr, 8–12 cm long; Sof-Flex Multi-Length Ureteral Stents; CookMedical Europe™) between renal pelvis and bladder. The transurethral bladder catheter is removed 16–18 h after surgery, and oral antibiotic prophylaxis is administered until the double-J catheter is removed.

The Cutting Balloon™ (Boston Scientific, Natick, MA, USA) catheter is reserved for those cases when the HPB notch or hourglass image does not completely disappear after 20 s at 16–18 atm. In those cases, a 3-, 4-, or 5-mm diameter CB and 2 cm length is inflated at the level of the ureteropelvic junction to up to 12 atm. Dilatation is then completed using a HPB as described before, and double-J ureteral stents is always placed. The antibiotic prophylaxis and urethral drainage protocol does not differ with respect to patients in whom HPB is used.

Double J stents are removed 4–6 weeks after the dilatation procedure and the UPJ is assessed (calibration) in day-hospital regimen. The calibration of the UPJ consists of the inflation of a balloon at low pressure (6–8 atm) in the UPJ to check the absence of residual stenosis. If a residual stenosis is found in the fluoroscopy, a new dilatation is then performed using an HPB. In these cases, a double-J stent is placed with a 4/0 Prolene suture attached to its distal tip and exteriorized (transurethral), being removed 1 week later in the outpatient clinic (pulling out the suture). Similar to the initial intervention, if the residual stenosis still persists after an HPB, a CB dilatation is then performed, and the double-J stent is removed in the daycare center 4 weeks later.
Postoperative Control
Follow-up consists in regular clinical review and renal ultrasonography at 3, 6, and 12 postoperative months, and then each 6 months until clinical and radiologic stabilization is observed. Antero-posterior renal pelvis diameter (APD, maximum pelvis diameter in a coronal view), pelvis/cortex ratio (PCR, Figure 1) and percentage of improvement (PI, Figure 1) of the APD are the main parameters used to predict the outcome. Postoperative MAG-3 diuretic renogram is performed only when a poor outcome is predicted at the six postoperative months attending to the ultrasonography parameters (when APD > 18.5 mm, PI < 35%, or PCR > 3.5). In case of UPJO recurrence, several minimally invasive options are posed: a new ERBD, CB dilatation or percutaneous anterograde endopyelotomy. In case of not being resolutive, an open dismembered pyeloplasty is performed and considered as a failure of the endourologic strategy.

RESULTS
Between July 2004 and September 2018, 112 patients with unilateral primary UPJO were treated with ERBD and met the inclusion criteria. Prenatal diagnosis of hydronephrosis was presented in 98 (87.5%) of them. Indications for surgery are shown in Table 1. Demographics, preoperative ultrasound findings and mean postoperative follow-up time are shown in Table 2. Mean follow-up time was 66.7 ± 37.5 months. A crossing lower pole vessel (exclusion criteria) was detected in five cases (bad evolution after an initial ERBD), and in four cases the diagnosis was made initially due to a high degree of clinical and radiologic suspicion.

Dilatation was successfully performed in 101 cases (90.2%). In 11 of these cases, the use of CB was needed in order to complete the dilatation. The diameters of HPB catheters used were 5 mm (n = 38), 6 mm (n = 51) and 7 mm (n = 12); diameters of CB were 3 mm (n = 3), 4 mm (n = 7), and 5 mm (n = 1). Mean surgical time was 24.4 ± 10.3 min, and there were no intraoperative complications. In 11 patients (9.8%), the retrograde HPB dilatation was not successful; causes of the failure and outcomes of these patients are shown in Table 3. Hospital stay was 24 h in 92 patients (82.1%), 48 h in 15 (13.4%) and more than 48 h in 5 (4.5%) due to preoperative urinary tract infection requiring intravenous antibiotics (n = 3) and to pain and vomiting (n = 2). In all patients, the analgesic medication consisted exclusively in non-steroidal anti-inflammatory drugs (no need of opioids). No oral analgesics were needed after discharge.

In the early postoperative period, 23 patients (22.8%) visited the emergency room to rule out a urinary tract infection, requiring an early double-J stent removal in only two cases [Clavien-Dindo III-b (22)]. Five patients required readmission because of pain and vomiting, and two due to persistent hematuria (Clavien-Dindo I). On those patients with a successful first intervention (101 patients), the double-J stent and UPJ calibration was performed and required an early double-J stent removal in only two cases [Clavien-Dindo III-b (22)]. Five patients required readmission because of pain and vomiting, and two due to persistent hematuria (Clavien-Dindo I). On those patients with a successful first intervention (101 patients), the double-J stent and UPJ calibration was performed and required an early double-J stent removal in only two cases [Clavien-Dindo III-b (22)].

In the late postoperative period, 23 patients (22.8%) visited the emergency room to rule out a urinary tract infection, requiring an early double-J stent removal in only two cases [Clavien-Dindo III-b (22)]. Five patients required readmission because of pain and vomiting, and two due to persistent hematuria (Clavien-Dindo I).
suture, placed on those with a weak inflammatory stenosis \( (n = 21) \), was removed 1 week later in the outpatient clinic, without incidences.

Follow-up ultrasound results are shown in Tables 4, 5. There was a statistically significant improvement in the reduction of postoperative APD, parenchymal thickness and PCR on those patients who required one or two ERBD \( (p < 0.05, t\)-test). Furthermore, there were no statistically significant differences on those variables between patients who required one or two dilatations \( (p > 0.05) \). Nine patients presented a late recurrence of UPJO despite the initial success, and an additional intervention was needed (mean of 12.4 postoperative months): an additional HPB dilatation \( (n = 3) \), a percutaneous endopyelotomy \( (n = 3) \), open pyeloplasty \( (n = 2) \) and nephrectomy due to loss of renal function \( (n = 1) \). Mean ultrasound measures of these nine patients at six postoperative months were: APD = 37.0 ± 9.9 mm, PCR = 5.9 ± 2.3 and PI = −8.5 ± 61.4%.

Outcomes of patients included in the study are shown in Figure 2. From the initial 112 patients, 76.8% of them \( (n = 86) \) required only one ERBD for the UPJO resolution. This percentage raises up to 86.6% \( (97\) patients) if those who required a second ERBD are included. Only seven patients \( (6.3\%) \) finally underwent an open pyeloplasty \( (6.3\%) \) and the other, a severe pre and postoperative pyelonephritis). The other six patients were treated with more than 2 ERBD \( (n = 3) \) or with a percutaneous endopyelotomy \( (n = 3) \).

From the 103 patients who did not require an open pyeloplasty, 40 presented almost one sonographic criteria for poor prognosis, requiring 15 of them \( (37.5\%) \) an additional intervention due to an obstructive diuretic drainage curve in the MAG-III renogram. From the 63 patients without any of these findings, only 2 \( (3.2\%) \) required an additional ERBD.

### DISCUSSION

In this study, we present our experience with the endourologic treatment of the congenital primary UPJO. The HPB dilatation is the core of the treatment, but the inclusion of the CB allowed a successful outcome in several cases with persistent stenosis despite the HPB inflation. We have previously reported good outcomes with the HPB \( (5) \) and the CB dilatation \( (18) \). In the present series, we report a success rate of 76.8% with one ERBD, and 86.6% when two ERBD where needed, which demonstrates the consistency of this technique in a significant number of patients and with a wide follow-up.

The minimally invasive options for the treatment of the UPJO have become more attractive in the recent years. Laparoscopic \( (23) \) and robot-assisted pyeloplasty had become more popular, showing promising results \( (3, 24) \). But concerns about its application in small children, a higher cost, the need of specific technology and demanding training make these options not universally available and applicable. In comparison, ERBD presents some advantages, as the reduction in the operative time and hospital stay \[ mean\ operative\ time\ of 240\ min\ and\ 1.5\–3.0\ days\ of\ hospital\ stay\ in\ recent\ laparoscopic\ and\ robotic\ series\ (3, 7, 23)\], less analgesics requirements (including opioids), the aesthetic benefits of the absence of scars, and its safe application in small infants. The complication rate is comparable, being the urinary infection the most frequent event. This could be related to the double-J placement, but we believe that its placement is imperative in order to avoid an acute postoperative UPJ obstruction \( (17) \). Finally, even that our success rate is slightly lower than the laparoscopic/robotic techniques, we strongly believe that the advantages of the endourologic approach make it an attractive and safe option in the treatment of the UPJO. However, as this technique does not alter the external anatomy of the ureter or renal pelvis, the surgical field is intact in case of needing a pyeloplasty.

Previous publications showed inconsistent results of the ERBD in children. Sugita et al. \( (25) \) reported a 47% success rate, and Wilkinson et al. \( (6) \) a successful treatment (combining retrograde and anterograde access) in 13/14 patients. Some authors, as Veenboer et al. \( (26) \), prefer the percutaneous anterograde approach, with reports of a high success in UPJO recurrences after pyeloplasty. In our experience, the improvement and adaptation of the endourologic tools to the pediatric population (especially with the use of \(<4\) Fr profile instruments), made the retrograde approach a safe, less invasive and feasible option even in infants, as we demonstrate with the low percentage of intraoperative complications reported. Due to the higher risk of complications, we prefer to reserve this therapeutic option for patients with UPJO recurrence \( (16) \).

Probably the main disadvantage of this procedure is that, in some cases \( (23\%) \) of our patients, a second dilatation procedure under general anesthesia is needed to achieve a persistent resolution of the stenosis. In our series, no anesthetic adverse
event was recorded, mainly due to the shortness and minimal invasiveness of the procedures (with a mean surgical time <30 min). Moreover, the learning curve is as needed as any other minimally invasive technique. Most part of our failures and recurrences were registered in the first half of the study, with a significative reduction of the number of failures in the last years (11 cases of failure or recurrences before year 2011, vs. 4 after that year).

Radiation exposure of the infants is an important concern in our practice. During the intervention, the operator reduces the effective dose to the minimum, and it is promoted the use of radiation shields where possible. Following the
recommendations of recent data (27–30), we have changed the postoperative image follow-up protocol and the postoperative MAG-III diuretic renogram is only performed on those patients with postoperative ultrasound worsening. Following this protocol, in up to 61 patients the MAG-3 diuretic renogram could have been avoided.

This study has the limitations of a retrospective design, without a control group. The learning curve of the technique is included in the long period of time for data collection, which could affect the outcome of the first patients included. It represents a single center experience, so prospective comparative studies should be encouraged to provide definitive evidence of this procedure. However, its success lies in the use of adequate endoscopic material suitable for pediatric age, the selection of appropriate hydrophilic guidewires (0.014"–0.018"), balloon catheters with low profile and proper double-J stents for small children.

**CONCLUSION**

The ERBD represents the least invasive option for the treatment of the congenital primary ureteropelvic junction obstruction. The outcome is acceptable with a very low rate of complications.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Normas de manejo de pacientes pediátricos, Comité Deontológico Hospital Gregorio Marañón. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

**AUTHOR CONTRIBUTIONS**

All authors contributed to the design of the research, data collection, analysis of the results, and writing of the manuscript. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Tan BJ, Smith AD. Ureteropelvic junction obstruction: repair: when, how, what? Curr Opin Urol. (2004) 14:55–9. doi: 10.1097/00042307-200403000-00002
2. O’Reilly PH, Broooman PJ, Mak S, Jones M, Pickup C, Atkinson C, et al. The long-term results of Anderson-Hynes pyeloplasty. BJU Int. (2001) 87:287–9. doi: 10.1046/j.1464-410x.2001.00108.x
3. Avery DI, Herbst KW, Lendvay TS, Dangle P, Gundeti MS, et al. Robot-assisted laparoscopic pyeloplasty: multi-institutional experience in infants. J Pediatr Urol. (2015) 11:139.e1–e5. doi: 10.1016/j.jpuro.2014.11.025
4. Huang Y, Wu Y, Shan W, Zeng L, Huang L. An updated meta-analysis of laparoscopic versus open pyeloplasty for ureteropelvic junction obstruction in children. Int J Clin Exp Med. (2015) 8:4922–31.
5. Parente A, Angulo JM, Romero RM, Rivas S, Burgos L, Tardaguila A. Management of ureteropelvic junction obstruction with high-pressure balloon dilatation: long-term outcome in 50 children under 18 months of age. Urology. (2013) 82:1138–44. doi: 10.1016/j.urology.2013.04.072
6. Wilkinson AG, Rajan P, MacKinlay GA. Endoluminal balloon dilatation for pelvi-ureteric junction obstruction in children: an effective alternative to open pyeloplasty. J Pediatr Urol. (2005) 1:301–5. doi: 10.1016/j.jpuro.2005.01.013
7. Varda BK, Wang Y, Chung BI, Lee RS, Kurtz MP, Nelson CP, et al. Has the robot caught up? National trends in utilization, perioperative outcomes, and cost for open, laparoscopic, and robotic pediatric pyeloplasty in the United States from 2003 to 2015. J Pediatr Urol. (2018) 14:336.e1–e8. doi: 10.1016/j.jpuro.2017.12.010
8. Song SH, Lee C, Jung I, Kim SJ, Park S, Park H, et al. A comparative study of pediatric open pyeloplasty, laparoscopy-assisted extracorporeal pyeloplasty, and robot-assisted laparoscopic pyeloplasty. PLoS ONE. (2017) 12:1–11. doi: 10.1371/journal.pone.0175026
9. Kadir S, White RI, Engel R. Balloon dilatation of a ureteropelvic junction obstruction. Radiology. (1982) 143:263–4. doi: 10.1148/radiology.143.1.7063737
10. Jacobs BL, Lai JC, Seelam R, Hanley JM, Wolf Jr JS, Hollenbeck BK, et al. The comparative effectiveness of treatments for ureteropelvic junction obstruction. Urology. (2018) 111:72–7. doi: 10.1016/j.urology.2017.09.002
11. Manikandan R, Saad A. Ten years’ experience of retrograde balloon dilatation of pelvi-ureteric junction obstruction [2]. BJU Int. (2004) 94:938. doi: 10.1111/j.1464-410x.2003.05132.2_x
12. Ortiz R, Parente A, Perez-Egido L, Burgos L, Angulo JM. Long-term outcomes in primary obstructive megaureter treated by endoscopic balloon dilatation. Experience after 100 cases. Front Pediatr. (2018) 6:1–9. doi: 10.3389/fped.2018.00275
13. Kassite L, Renua Petel M, Chaussy Y, Eysaertier E, Alzahrani K, Szwarz C, et al. High pressure balloon dilatation of primary obstructive megaureter in children: a multicenter study. Front Pediatr. (2018) 6:1–6. doi: 10.3389/fped.2018.00329
14. Patel T, Kellner CP, Katsumi H, Gupta M. Efficacy of endopyelotomy in patients with secondary ureteropelvic junction obstruction. J Endoural. (2011) 25:587–91. doi: 10.1098/end.2010.0026
15. Kim EH, Tanagho YS, Traxel EJ, Austin PF, Figenshau RS, Coplen DE. Endopyelotomy for pediatric ureteropelvic junction obstruction: a review of our 25-year experience. J Urol. (2012) 188(4 Suppl.):1628–33. doi: 10.1016/j.juro.2012.02.016
16. Parente A, Angulo JM, Burgos L, Romero RM, Rivas S, Ortiz R. Percutaneous endopyelotomy over high pressure balloon for recurrent ureteropelvic junction obstruction in children. J Urol. (2015) 194:184–9. doi: 10.1016/j.juro.2015.01.074
17. MacKenzie RK, Youngson GG, Hussey JK, Mahomed AA. Is there a role for balloon dilatation of pelvi-ureteric obstruction in children? J Pediatr Surg. (2002) 37:893–6. doi: 10.1053/jpsu.2002.32905
18. Parente A, Perez-Egido L, Romero RM, Ortiz R, Burgos L, Angulo JM. Retrograde endopyelotomy with cutting balloonTM for treatment of ureteropelvic junction obstruction in infants. Front Pediatr. (2016) 4:1–5. doi: 10.3389/fped.2016.00072
19. Longpre M, Nguan A, MacNeil AE, Afsar K. Prediction of the outcome of antenatally diagnosed hydronephrosis: a multivariable analysis. J Pediatr Urol. (2012) 8:135–9. doi: 10.1016/j.jpuro.2011.05.013
20. Braga LH, McGrath M, Farrokhlyar F, Jegatheeswaran K, Lorenzo AJ. Society for Fetal Urology Classification Vs Urinary Tract Dilation Grading System For Prognostication In Prenatal Hydronephrosis: A Time To Resolution Analysis. J Urol. (2018) 199:1615–21. doi: 10.1016/j.juro.2017.11.077
21. Gordon I, Piepsz A, Sixt R. Guidelines for standard and diuretic renogram in children. *Eur J Nucl Med Mol Imaging*. (2011) 38:175–88. doi: 10.1007/s00259-011-1811-3

22. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*. (2004) 240:205–13. doi: 10.1097/01.sla.0000133083.54934.ax

23. Tam YH, Pang KKY, Wong YS, Chan KW, Lee KH. From laparoscopic pyeloplasty to robot-assisted laparoscopic pyeloplasty in primary and reoperative repairs for ureteropelvic junction obstruction in children. *J Laparoendosc Adv Surg Tech*. (2018) 28:1012–8. doi: 10.1089/lap.2017.0561

24. Satyanarayan A, Peters CA. Advances in robotic surgery for pediatric ureteropelvic junction obstruction and vesicoureteral reflux: history, present, and future. *World J Urol*. (2020) 38:1821–6. doi: 10.1007/s00345-019-02753-3

25. Sugita Y. Retrograde balloon dilatation for primary pelviureteric junction stenosis in children. *Br J Urol*. (1996) 77:587–9. doi: 10.1046/j.1464-410X.1996.94520.x

26. Veenboer PW, Chrzan R, Dik P, Klijn AJ, De Jong TPVM. Secondary endoscopic pyelotomy in children with failed pyeloplasty. *Urology*. (2011) 77:1450–4. doi: 10.1016/j.urology.2010.10.021

27. Cost NG, Prieto JC, Wilcox DT. Screening ultrasound in follow-up after pediatric pyeloplasty. *Urology*. (2010) 76:175–9. doi: 10.1016/j.urology.2009.09.092

28. Rickard M, Braga LH, Oliveira JP, Romao R, Demaria J, Lorenzo AJ. Percent improvement in renal pelvis antero-posterior diameter (PI-APD): prospective validation and further exploration of cut-off values that predict success after pediatric pyeloplasty supporting safe monitoring with ultrasound alone. *J Pediatr Urol*. (2016) 12:228.e1–e6. doi: 10.1016/j.jpurol.2016.04.003

29. Babu R, Sai V. Pelvis/cortex ratio: an early marker of success following pyeloplasty in children. *J Pediatr Urol*. (2010) 6:473–6. doi: 10.1016/j.jpurol.2009.12.004

30. Helmy TE, Harraz A, Sharaf DE, El Demerdash Y, Hafez AT, Gad H, et al. Can renal ultrasonography predict early success after pyeloplasty in children? A prospective study. *Urol Int*. (2014) 93:406–10. doi: 10.1159/000362504

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ordóñez, Ortiz, Parente, Burgos, Fernández-Bautista, Pérez-Egido and Angulo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.